WO2005016949A3 - Derives d'acide sialique - Google Patents

Derives d'acide sialique Download PDF

Info

Publication number
WO2005016949A3
WO2005016949A3 PCT/GB2004/003484 GB2004003484W WO2005016949A3 WO 2005016949 A3 WO2005016949 A3 WO 2005016949A3 GB 2004003484 W GB2004003484 W GB 2004003484W WO 2005016949 A3 WO2005016949 A3 WO 2005016949A3
Authority
WO
WIPO (PCT)
Prior art keywords
sialic acid
acid derivatives
passivated
instance
polysialic acids
Prior art date
Application number
PCT/GB2004/003484
Other languages
English (en)
Other versions
WO2005016949A2 (fr
Inventor
Sanjay Jain
Gregory Gregoriadis
Original Assignee
Lipoxen Technologies Ltd
Sanjay Jain
Gregory Gregoriadis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd, Sanjay Jain, Gregory Gregoriadis filed Critical Lipoxen Technologies Ltd
Publication of WO2005016949A2 publication Critical patent/WO2005016949A2/fr
Publication of WO2005016949A3 publication Critical patent/WO2005016949A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C07K17/12—Cellulose or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan

Abstract

Des unités réductrices d'acide sialique sont passivées, par exemple par réduction, ou par amination réductrice ou par coiffage. Ledit procédé est utile pour produire des composés d'acide sialique chimiquement inertes, en particulier des acides polysialiques destinés par exemple à être utilisés en tant qu'excipients, tels que des véhicules, des diluants, des modificateurs de viscosité, des agents de rétention de l'humidité, etc. Des acides polysialiques passivés peuvent être des agents thérapeutiques utiles.
PCT/GB2004/003484 2003-08-12 2004-08-12 Derives d'acide sialique WO2005016949A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03254989.1 2003-08-12
EP03254989 2003-08-12

Publications (2)

Publication Number Publication Date
WO2005016949A2 WO2005016949A2 (fr) 2005-02-24
WO2005016949A3 true WO2005016949A3 (fr) 2005-03-31

Family

ID=34178604

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2004/003511 WO2005016974A1 (fr) 2003-08-12 2004-08-12 Derive d'acide sialique destine a la derivatisation et a la conjugaison proteinique
PCT/GB2004/003484 WO2005016949A2 (fr) 2003-08-12 2004-08-12 Derives d'acide sialique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/003511 WO2005016974A1 (fr) 2003-08-12 2004-08-12 Derive d'acide sialique destine a la derivatisation et a la conjugaison proteinique

Country Status (7)

Country Link
US (4) US7807824B2 (fr)
EP (1) EP1654290B1 (fr)
JP (1) JP4566194B2 (fr)
KR (1) KR101113726B1 (fr)
ES (1) ES2735809T3 (fr)
RU (1) RU2333223C2 (fr)
WO (2) WO2005016974A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807824B2 (en) * 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
CN101039964B (zh) * 2004-08-12 2012-11-14 利普生技术有限公司 带电多糖的分级
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR101400105B1 (ko) * 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
CA2670618C (fr) 2006-12-15 2016-10-04 Baxter International Inc. Conjugue du facteur viia et de l'acide (poly)sialique presentant une demi-vie in vivo prolongee
PL2115010T3 (pl) * 2007-02-28 2012-07-31 Lipoxen Tech Limited Zmniejszanie zawartości endotoksyny w kwasach polisialowych
WO2008113192A1 (fr) * 2007-03-16 2008-09-25 Bien-Air Holding S.A. Piece a main a usage dentaire ou chirurgical
JP4966434B2 (ja) * 2008-10-15 2012-07-04 バクスター・インターナショナル・インコーポレイテッド 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
TW201042257A (en) * 2009-05-26 2010-12-01 Baxter Int Detection of antibody that binds to water soluble polymer-modified polypeptides
KR101912335B1 (ko) * 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
NZ623810A (en) 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
RU2522846C2 (ru) * 2009-11-30 2014-07-20 Российская Федерация, От Имени Которой Выступает Министерство Промышленности И Торговли Российской Федерации Лекарственный препарат и способ улучшения реологических свойств мокроты и ингаляционное применение такого препарата
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
MX346271B (es) 2010-07-30 2016-07-08 Baxalta Inc Catalizadores nucleofílicos para enlace de oxima.
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
EP3412314A1 (fr) 2011-05-27 2018-12-12 Baxalta GmbH Protéines thérapeutiques conjuguées au poly(acide sialique) et leurs procédés de préparation
WO2012170969A2 (fr) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Composés pro-coagulants et leurs procédés d'utilisation
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
NZ626945A (en) 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
KR20190094480A (ko) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
EP2858659B1 (fr) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Composés pro-coagulants
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
WO2014170496A1 (fr) 2013-04-18 2014-10-23 Novo Nordisk A/S Co-agonistes stables du récepteur du glucagon/glp -1 à action retardée et à usage médical
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3903599A1 (fr) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. Procédés d'inactivation de virus sur colonne
WO2015070014A1 (fr) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Composé de fusion procoagulant
SI3091997T1 (sl) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Himerni proteini faktorja VIII in njihova uporaba
WO2015130963A2 (fr) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions et méthodes d'administration au cerveau de protéine insuline ou insulinoïde
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
EP3197481A1 (fr) 2014-09-26 2017-08-02 Bayer Pharma Aktiengesellschaft Dérivés d'adrénomédulline stabilisés et leur utilisation
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
AU2016362606A1 (en) 2015-12-03 2018-06-28 Takeda Pharmaceutical Company Limited Factor VIII with extended half-life and reduced ligand-binding properties
MA45473A (fr) 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations
CZ308106B6 (cs) * 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
WO2018175752A1 (fr) * 2017-03-22 2018-09-27 Genentech, Inc. Compositions d'anticorps optimisées pour le traitement de troubles oculaires
US20190083636A1 (en) 2017-04-25 2019-03-21 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2018197545A1 (fr) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Procédés de traitement de myélomes multiples exprimant des niveaux élevés de récepteur d'epo à l'aide de psa-epo
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
PE20210632A1 (es) 2018-07-03 2021-03-23 Bristol Myers Squibb Co Formulaciones de fgf-21
WO2020099513A1 (fr) 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glyco-polysialylation de blinatumomab
JP2022519586A (ja) * 2019-02-04 2022-03-24 ゼネティック バイオサイエンシーズ インコーポレイテッド 糖ポリシアル酸化治療用タンパク質を使用する方法
EP3986918A1 (fr) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Analogues d'adrénomédulline pour stabilisation à long terme et leur utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273388A2 (fr) * 1986-12-29 1988-07-06 Mect Corporation Dérivés de l'acide sialique ayant un groupe carbonyl réactif
EP0454898A1 (fr) * 1990-03-30 1991-11-06 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Protéine modifiée avec glycosaminoglycanes, son procédé de production et compositions pharmaceutiques le contenant
WO1998015566A1 (fr) * 1996-10-08 1998-04-16 Macquarie Research Ltd. Derives de glycane
EP1035137A1 (fr) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Procédé d'amination réductrice des polysaccharides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US375010A (en) * 1887-12-20 Chaeles a
US375006A (en) * 1887-12-20 Lafayette w
US375008A (en) * 1887-12-20 Die for making wood type
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
JP2637845B2 (ja) 1989-12-14 1997-08-06 ナシヨナル・リサーチ・カウンシル・カナダ 修飾メニンゴコツクス多糖複合ワクチン
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5352670A (en) * 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
US5329028A (en) * 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
WO2001087922A2 (fr) 2000-05-16 2001-11-22 Lipoxen Technologies Limited Derivatisation de proteines
US7807824B2 (en) * 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2005016973A1 (fr) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Derives d'acide polysialique
KR101400105B1 (ko) * 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273388A2 (fr) * 1986-12-29 1988-07-06 Mect Corporation Dérivés de l'acide sialique ayant un groupe carbonyl réactif
EP0454898A1 (fr) * 1990-03-30 1991-11-06 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Protéine modifiée avec glycosaminoglycanes, son procédé de production et compositions pharmaceutiques le contenant
WO1998015566A1 (fr) * 1996-10-08 1998-04-16 Macquarie Research Ltd. Derives de glycane
EP1035137A1 (fr) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Procédé d'amination réductrice des polysaccharides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WINZLER R. J.: "Effect of periodate oxidation and borohydride reduction on the biology of the major glycoprotein of human erythrocytes", CELL. ANTIGENS, LECT. SUM. CONF. 1972, MEETING DATE 1971, vol. 1972, 1972, pages 145 - 152, XP008042203 *

Also Published As

Publication number Publication date
US9452224B2 (en) 2016-09-27
RU2333223C2 (ru) 2008-09-10
KR101113726B1 (ko) 2012-02-27
WO2005016949A2 (fr) 2005-02-24
US20140220046A1 (en) 2014-08-07
US20170007706A1 (en) 2017-01-12
EP1654290A1 (fr) 2006-05-10
US8653255B2 (en) 2014-02-18
US20110082077A1 (en) 2011-04-07
US7807824B2 (en) 2010-10-05
EP1654290B1 (fr) 2019-03-13
RU2006107546A (ru) 2007-09-20
KR20060096981A (ko) 2006-09-13
US20070191597A1 (en) 2007-08-16
US10406209B2 (en) 2019-09-10
JP2007501889A (ja) 2007-02-01
ES2735809T3 (es) 2019-12-20
JP4566194B2 (ja) 2010-10-20
WO2005016974A1 (fr) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2005016949A3 (fr) Derives d'acide sialique
WO2003097656A3 (fr) Nouveaux derivés anticonvulsifs à substitution sulfamate
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
IL176062A0 (en) Dpp-iv inhibitors
RS20050939A (en) Pyrido/2,1-a/isoquinoline derivatives as dpp-iv inhibitors
AU2003234790A1 (en) Process for producing mevalonic acid
EP1652848A4 (fr) Procede pour produire un compose imide
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2006058628A3 (fr) Derives benzoquinolizine substitues
WO2006133397A3 (fr) Procede permettant de realiser la synthese de triazoles
CA2585802A1 (fr) Procede industriel de synthese de la .gamma.-lactone de l'acide 17-hydroxy-6.beta.,7.beta.;15.beta.,16.beta.-bismethylene-3-oxo-17.alpha.-pregn-4-ene-21-carboxylique et intermediaires-cles de ce procede
WO2005048954A3 (fr) Procede continu de production d'hydroxyazapirones par oxydation
IL186014A0 (en) Process for the preparation of 2-azabicyclo[3.3.0] octane-3-carboxylic acid derivatives
AP2277A (en) Process for production of 1,2,2,2-tertafluoro ethyl difluoro methyl ether.
WO2006080043A3 (fr) Composes organiques convenant pour le traitement de la maladie d'alzheimer, utilisation et methode de fabrication
AU2003258667A1 (en) Method for the production by fermentation of sulphur-containing fine chemicals (metf)
WO2004089863A8 (fr) Procede pour produire un sel d'ammonium d'acide 2-hydroxy-4-methylthiobutyrique
WO2007057767A3 (fr) Derives d'acides amines
WO2006084941A3 (fr) Procede d'elaboration
EP1571144A4 (fr) Compose diamine cyclique hydroxyalkyle
EP1669458A4 (fr) Procede de production d'un acide 1,4-dihydoxy-2-naphtoique
WO2006099940A8 (fr) 8-pyrrolidino-benzimidazoles bicycliques substitues, leur procede de production, et leur utilisation en tant que medicaments
GEP20074025B (en) Process for preparing acid salts of gemifloxacin
WO2006090265A3 (fr) Procedes de preparation de levetiracetam, son intermediaire et utilisation de levetiracetam dans des compositions pharmaceutiques
MXPA05001967A (es) Proceso para la produccion de derivado de indolopirrolocarbazol.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase